190 related articles for article (PubMed ID: 37367101)
1. Inhibitory effects of a maleimide compound on the virulence factors of
Li Y; Chen C; Cong L; Mao S; Shan M; Han Z; Mao J; Xie Z; Zhu Z
Virulence; 2023 Dec; 14(1):2230009. PubMed ID: 37367101
[TBL] [Abstract][Full Text] [Related]
2. Biatriosporin D displays anti-virulence activity through decreasing the intracellular cAMP levels.
Zhang M; Chang W; Shi H; Zhou Y; Zheng S; Li Y; Li L; Lou H
Toxicol Appl Pharmacol; 2017 May; 322():104-112. PubMed ID: 28286116
[TBL] [Abstract][Full Text] [Related]
3. Development of Anti-Virulence Approaches for Candidiasis via a Novel Series of Small-Molecule Inhibitors of
Romo JA; Pierce CG; Chaturvedi AK; Lazzell AL; McHardy SF; Saville SP; Lopez-Ribot JL
mBio; 2017 Dec; 8(6):. PubMed ID: 29208749
[No Abstract] [Full Text] [Related]
4. The inhibition of trans-cinnamaldehyde on the virulence of Candida albicans via enhancing farnesol secretion with low potential for the development of resistance.
Ying L; Mingzhu S; Mingju Y; Ye X; Yuechen W; Ying C; Bing G; Hongchun L; Zuobin Z
Biochem Biophys Res Commun; 2019 Aug; 515(4):544-550. PubMed ID: 31176484
[TBL] [Abstract][Full Text] [Related]
5. Retigeric acid B attenuates the virulence of Candida albicans via inhibiting adenylyl cyclase activity targeted by enhanced farnesol production.
Chang W; Li Y; Zhang L; Cheng A; Lou H
PLoS One; 2012; 7(7):e41624. PubMed ID: 22848547
[TBL] [Abstract][Full Text] [Related]
6. Streptococcus mutans sigX-inducing peptide inhibits the virulence of Candida albicans and oral candidiasis through the Ras1-cAMP-Efg1 pathway.
Zhang K; Sun IG; Liao B; Yang Y; Ma H; Jiang A; Chen S; Guo Q; Ren B
Int J Antimicrob Agents; 2023 Aug; 62(2):106855. PubMed ID: 37211262
[TBL] [Abstract][Full Text] [Related]
7. Repurposing Pilocarpine Hydrochloride for Treatment of Candida albicans Infections.
Nile C; Falleni M; Cirasola D; Alghamdi A; Anderson OF; Delaney C; Ramage G; Ottaviano E; Tosi D; Bulfamante G; Morace G; Borghi E
mSphere; 2019 Jan; 4(1):. PubMed ID: 30674648
[TBL] [Abstract][Full Text] [Related]
8.
Romo JA; Pierce CG; Esqueda M; Hung CY; Saville SP; Lopez-Ribot JL
Front Cell Infect Microbiol; 2018; 8():227. PubMed ID: 30042929
[TBL] [Abstract][Full Text] [Related]
9. Chitosan nanoparticles encapsulating farnesol evaluated in vivo against Candida albicans.
Costa AF; da Silva JT; Martins JA; Rocha VL; de Menezes LB; Amaral AC
Braz J Microbiol; 2024 Mar; 55(1):143-154. PubMed ID: 37964169
[TBL] [Abstract][Full Text] [Related]
10. The Anti-Biofilm Efficacy of Caffeic Acid Phenethyl Ester (CAPE)
de Barros PP; Rossoni RD; Garcia MT; Kaminski VL; Loures FV; Fuchs BB; Mylonakis E; Junqueira JC
Front Cell Infect Microbiol; 2021; 11():700305. PubMed ID: 34408988
[No Abstract] [Full Text] [Related]
11. Effect of farnesol on a mouse model of systemic candidiasis, determined by use of a DPP3 knockout mutant of Candida albicans.
Navarathna DH; Hornby JM; Krishnan N; Parkhurst A; Duhamel GE; Nickerson KW
Infect Immun; 2007 Apr; 75(4):1609-18. PubMed ID: 17283095
[TBL] [Abstract][Full Text] [Related]
12. The novel antifungal agent AB-22 displays in vitro activity against hyphal growth and biofilm formation in Candida albicans and potency for treating systemic candidiasis.
Lee KT; Lee DG; Choi JW; Park JH; Park KD; Lee JS; Bahn YS
J Microbiol; 2022 Apr; 60(4):438-443. PubMed ID: 35286605
[TBL] [Abstract][Full Text] [Related]
13. Transdermal administration of farnesol-ethosomes enhances the treatment of cutaneous candidiasis induced by
Shen T; Tian B; Liu W; Yang X; Sheng Q; Li M; Wang H; Wang X; Zhou H; Han Y; Ding C; Sai S
Microbiol Spectr; 2024 Apr; 12(4):e0424723. PubMed ID: 38415658
[TBL] [Abstract][Full Text] [Related]
14. Magnesium deprivation affects cellular circuitry involved in drug resistance and virulence in Candida albicans.
Hans S; Fatima Z; Hameed S
J Glob Antimicrob Resist; 2019 Jun; 17():263-275. PubMed ID: 30659981
[TBL] [Abstract][Full Text] [Related]
15. The possible molecular mechanisms of farnesol on the antifungal resistance of C. albicans biofilms: the regulation of CYR1 and PDE2.
Chen S; Xia J; Li C; Zuo L; Wei X
BMC Microbiol; 2018 Dec; 18(1):203. PubMed ID: 30509171
[TBL] [Abstract][Full Text] [Related]
16. Suppression of the pathogenicity of Candida albicans by the quorum-sensing molecules farnesol and tryptophol.
Singkum P; Muangkaew W; Suwanmanee S; Pumeesat P; Wongsuk T; Luplertlop N
J Gen Appl Microbiol; 2020 Jan; 65(6):277-283. PubMed ID: 31217414
[TBL] [Abstract][Full Text] [Related]
17. Antifungal activity of ribavirin used alone or in combination with fluconazole against Candida albicans is mediated by reduced virulence.
Zhang M; Yan H; Lu M; Wang D; Sun S
Int J Antimicrob Agents; 2020 Jan; 55(1):105804. PubMed ID: 31605727
[TBL] [Abstract][Full Text] [Related]
18. The in vitro and in vivo efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a murine vulvovaginitis model.
Bozó A; Domán M; Majoros L; Kardos G; Varga I; Kovács R
J Microbiol; 2016 Nov; 54(11):753-760. PubMed ID: 27796932
[TBL] [Abstract][Full Text] [Related]
19. Anti-virulence strategy of diaryl chalcogenide compounds against
Song S; Zhao S; Sun X; Meng L; Wang Z; Tan H; Liu J; Zhang M; Deng Y
Virulence; 2023 Dec; 14(1):2265012. PubMed ID: 37771181
[No Abstract] [Full Text] [Related]
20. Anticandidal Activity of Kalopanaxsaponin A: Effect on Proliferation, Cell Morphology, and Key Virulence Attributes of
Li Y; Shan M; Yan M; Yao H; Wang Y; Gu B; Zhu Z; Li H
Front Microbiol; 2019; 10():2844. PubMed ID: 31849923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
